Literature DB >> 10712265

Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver.

E M Zimmermann1, L Li, E C Hoyt, J B Pucilowska, S Lichtman, P K Lund.   

Abstract

The liver is a major source of circulating insulin-like growth factor I (IGF-I), and it also synthesizes several classes of IGF binding proteins (IGFBPs). Synthesis of IGF-I and IGFBPs is regulated by hormones, growth factors, and cytokines. They are nutritionally regulated and expressed in developmentally specific patterns. To gain insight into cellular regulatory mechanisms that determine hepatic synthesis of IGF-I and IGFBPs and to identify potential target cells for IGF-I within the liver, we studied the cellular sites of synthesis of IGF-I, IGF receptor, growth hormone (GH) receptor, and IGFBPs in freshly isolated rat hepatocytes, endothelial cells, and Kupffer cells. We also localized cellular sites of IGFBP synthesis by in situ hybridization histochemistry. Western ligand and immunoblot analyses were used to determine IGFBP secretion by isolated cells. Two IGF-I mRNA subtypes with different 5' ends (class 1 and class 2) were detected in all isolated liver cell preparations. Type 1 IGF receptor mRNA was detected in endothelial cells, indicating that these cells are a local target for IGF actions in liver. GH receptor was expressed in all cell preparations, consistent with GH regulation of IGF-I and IGFBP synthesis in multiple liver cell types. The IGFBPs expressed striking cell-specific expression. IGFBP-1 was synthesized only in hepatocytes, and IGFBP-3 was expressed in Kupffer and endothelial cells. IGFBP-4 was expressed at high levels in hepatocytes and at low levels in Kupffer and endothelial cells. Cell-specific expression of distinct IGFBPs in the liver provides the potential for cell-specific regulation of hepatic and endocrine actions of IGF-I.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712265     DOI: 10.1152/ajpgi.2000.278.3.G447

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  19 in total

Review 1.  Insulin-like growth factors in the gastrointestinal tract and liver.

Authors:  John F Kuemmerle
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

2.  Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury.

Authors:  S Sanz; J B Pucilowska; S Liu; C M Rodríguez-Ortigosa; P K Lund; D A Brenner; C R Fuller; J G Simmons; A Pardo; M-L Martínez-Chantar; J A Fagin; J Prieto
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 3.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

Review 4.  IGF-I/IGFBP system: metabolism outline and physical exercise.

Authors:  R Gatti; E F De Palo; G Antonelli; P Spinella
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

5.  Transcriptional activation of endothelial cells by TGFβ coincides with acute microvascular plasticity following focal spinal cord ischaemia/reperfusion injury.

Authors:  Richard L Benton; Melissa A Maddie; Toros A Dincman; Theo Hagg; Scott R Whittemore
Journal:  ASN Neuro       Date:  2009-08-26       Impact factor: 4.146

6.  GTPase ARFRP1 is essential for normal hepatic glycogen storage and insulin-like growth factor 1 secretion.

Authors:  Deike Hesse; Alexander Jaschke; Timo Kanzleiter; Nicole Witte; Robert Augustin; Angela Hommel; Gerhard Paul Püschel; Klaus-Jürgen Petzke; Hans-Georg Joost; Michael Schupp; Annette Schürmann
Journal:  Mol Cell Biol       Date:  2012-08-27       Impact factor: 4.272

7.  Heterogeneous expression of suppressor of cytokine signalling 2 (SOCS-2) in liver tissue.

Authors:  Sebastian Zellmer; Stephan Sickinger; Wolfgang Schmidt-Heck; Reinhard Guthke; Rolf Gebhardt
Journal:  J Anat       Date:  2009-05-14       Impact factor: 2.610

8.  Insulin-like growth factors in patients with liver cysts.

Authors:  Olgica Nedić; J Anna Nikolić; Ivona Baricević; Biljana Jovanović; Natasa Ilić
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

9.  Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis.

Authors:  Marketa Jirouskova; Olga Zbodakova; Martin Gregor; Karel Chalupsky; Lenka Sarnova; Marian Hajduch; Jiri Ehrmann; Marie Jirkovska; Radislav Sedlacek
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS.

Authors:  Arseny Finkelstein; Gilad Kunis; Akop Seksenyan; Ayal Ronen; Tamara Berkutzki; David Azoulay; Maya Koronyo-Hamaoui; Michal Schwartz
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.